The 2026 AIPPI World Congress, held in Hamburg from 7 to 10 October, brought together IP practitioners, judges, industry representatives and academics from around the world. Its patent programme…
A second medical use patent is often seen as an easy target. The Milan section of the UPC Central Division has just shown that it is much harder to hit when the challenger is required to say exactly…
Remember the caps? In March 2021 this blog asked what it is with the Dutch and money, and reported that the Dutch patent courts had put indication tariffs on recoverable legal costs. Simple case,…
Technical contribution: analysis of three recent opinions from the Brazilian PTO's second instanceThe Brazilian Patent and Trademark Office's appeal body (CGREC/COREP) issued technical opinions…
In two of its recent decisions (apixaban and sacubitril-valsartan), the Czech Industrial Property Office (CZ IPO) has considered the application of decision G-2/21 (plausibility) of the Enlarged…
A divisional is worth what it allows its owner to argue later. G 1/25, and the referral now pending as G 1/26, sharpen a familiar point: that value comes from the choices made at filing and during…
G 1/25 contains two principles that can pull against each other. A definition in the description may determine the meaning attributed to a claim term, but the description and drawings cannot be used…
BackgroundSPCs are granted for “products”. Products are defined as active ingredients or combinations of active ingredients (Art. 1(b) SPC Regulation). But what constitutes an active ingredient? The…
The disclosure decision comes firstA comparable licence is never only evidence of a rate. Before the Unified Patent Court, pleading one may open it to an employee of the opponent, keep that employee…
A compass worth havingThe 7th Civil Chamber of the Landgericht München I has done something no European court had done before. On 13 August 2026 it published guidelines, sixty-seven pages long,…
